CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 5 enrolled
Drug / intervention
tofacitinibdrug
Likely dose
tofacitinib 11mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03580343
NCT03580343Phase 2Unknown

Tofacitinib for the Treatment of Inflammatory Eye Disease

Washington University School of Medicine·interventional·Posted Jul 9, 2018·Updated Feb 1, 2021

In Brief

A Phase 2 clinical trial evaluating tofacitinib for Uveitis and Scleritis. Targeting 5 participants across 1 site.

Detailed Summary

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Scleritis
CountriesUnited States
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedJul 9, 2018
Enrollment StartApr 4, 2019
Primary CompletionDec 1, 2019
Study CompletionApr 4, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.0 years ago

Interventions

tofacitinibdrug

tofacitinib extended release, 11mg, daily, oral